Is beyond air a good stock to buy?

Beyond Air has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. Beyond Air has only been the subject of 1 research reports in the past 90 days.

Should you buy beyond air (xair) stock?

There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XAIR shares. View XAIR analyst ratings or view top-rated stocks. What is Beyond Air's stock price target for 2024? 3 Wall Street analysts have issued 1-year price objectives for Beyond Air's stock.

What is beyond air?

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.